dc.contributor.author |
Choi, Peter |
en |
dc.contributor.author |
Sutherland, Hamish |
en |
dc.contributor.author |
Tong, Amy ST |
en |
dc.contributor.author |
Blaser, Adrian |
en |
dc.contributor.author |
Franzblau, Scott G |
en |
dc.contributor.author |
Cooper, Christopher B |
en |
dc.contributor.author |
Lotlikar, Manisha U |
en |
dc.contributor.author |
Upton, Anna M |
en |
dc.contributor.author |
Guillemont, Jerome |
en |
dc.contributor.author |
Motte, Magali |
en |
dc.contributor.author |
Queguiner, Laurence |
en |
dc.contributor.author |
Andries, Koen |
en |
dc.contributor.author |
Van den Broeck, Walter |
en |
dc.contributor.author |
Denny, William |
en |
dc.contributor.author |
Palmer, Brian |
en |
dc.date.accessioned |
2018-11-19T01:41:42Z |
en |
dc.date.issued |
2017-12 |
en |
dc.identifier.issn |
0960-894X |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/44451 |
en |
dc.description.abstract |
Analogues of bedaquiline where the phenyl B-unit was replaced with monocyclic heterocycles of widely differing lipophilicity (thiophenes, furans, pyridines) were synthesised and evaluated. While there was an expected broad positive correlation between lipophilicity and anti-TB activity, the 4-pyridyl derivatives appeared to have an additional contribution to antibacterial potency. The majority of the compounds were (desirably) more polar and had higher rates of clearance than bedaquiline, and showed acceptable oral bioavailability, but there was only limited (and unpredictable) improvement in their hERG liability. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
Bioorganic & medicinal chemistry letters |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Microsomes, Liver |
en |
dc.subject |
Animals |
en |
dc.subject |
Humans |
en |
dc.subject |
Rats |
en |
dc.subject |
Mycobacterium tuberculosis |
en |
dc.subject |
Heterocyclic Compounds |
en |
dc.subject |
Antitubercular Agents |
en |
dc.subject |
Microbial Sensitivity Tests |
en |
dc.subject |
Administration, Oral |
en |
dc.subject |
Inhibitory Concentration 50 |
en |
dc.subject |
Structure-Activity Relationship |
en |
dc.subject |
Half-Life |
en |
dc.subject |
Diarylquinolines |
en |
dc.subject |
ERG1 Potassium Channel |
en |
dc.title |
Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1016/j.bmcl.2017.10.042 |
en |
pubs.issue |
23 |
en |
pubs.begin-page |
5190 |
en |
pubs.volume |
27 |
en |
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
29107541 |
en |
pubs.end-page |
5196 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
brief-report |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
en |
pubs.subtype |
Research Support, U.S. Gov't, Non-P.H.S. |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
708572 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
dc.identifier.eissn |
1464-3405 |
en |
pubs.record-created-at-source-date |
2017-11-07 |
en |
pubs.dimensions-id |
29107541 |
en |